A New Cell-Cycle Target in Cancer — Inhibiting Cyclin D–Dependent Kinases 4 and 6

Orally available drugs that potently and specifically inhibit the activities of the cyclin D–dependent kinases CDK4 and CDK6 represent paradigm-shifting antineoplastic agents. Unlike traditional cytotoxic drugs, which kill dividing cells by interfering with DNA replication (S phase) or mitosis (M…

http://ift.tt/2fk0cXp